LOS ANGELES, CA--(Marketwired - May 20, 2013) - MyMedicalRecords, Inc. ("MMR"), a wholly owned subsidiary of MMRGlobal, Inc. (
The complaint alleges that Jardogs, while infringing on MMR's patent, also has induced others including Allscripts, distributors, agents, resellers and users to infringe one or more claims of the patent.
According to Robert H. Lorsch, MMRGlobal CEO, "MMR's business is selling our Personal Health Record products and services and monetizing our patents and other intellectual property both domestically and internationally. We are currently focused on meeting with large hospital groups, retail pharmacies, laboratory systems, EHR and PHR vendors and physician groups. As I have stated in the past, our preferred course is to always create reasonable business solutions where both sides feel like winners. As part of those efforts, we are continuing to send hundreds of letters to hospitals and healthcare professionals. Based on conversations and meetings I continue to attend, I am optimistic that those efforts will be successful."
MMR is a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions, and MMRPro document management and imaging systems for healthcare professionals. MMR currently has seven U.S. health IT patents: U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240. The MMR Patent Portfolio includes nearly 400 claims as well as additional applications and continuation applications. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South Korea, Israel, and European nations.
Additionally, MMRGlobal holds numerous biotech patents which were acquired through a 2009 reverse merger with San Diego-based biotechnology company Favrille, Inc. The portfolio currently includes three U.S. patents pertaining to the manufacturing of compositions for B-cell vaccines used in the fight against lymphoma and potentially other forms of cancer as well as additional patents for anti-CD20 monoclonal antibodies. The Company also has five U.S. pending patent applications, eight patents in foreign countries and 15 pending patent applications in foreign countries as well as patient samples and other IP, which are also the subject of 13 million dollars in current licensing agreements.
For additional information regarding the MyMedicalRecords, Inc. complaint against Jardogs LLC, contact Ted Ward at Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384.
About MMRGlobal MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro , is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com . View demos and video tutorials of the Company's products and services at www.mmrtheater.com .
Forward-Looking Statements All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; research and valuation reports on the Company; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
CONTACT: Michael Selsman Public Communications Co. ms@publiccommunications.biz (310) 922-7033
